sur IPSEN (EPA:IPN)
Update on Ipsen's Phase III BOLD Trial in Biliary Atresia
On July 24, 2026, Ipsen announced that the Phase III BOLD trial for biliary atresia did not meet its primary endpoint. The trial evaluated the efficacy of Bylvay (odevixibat) compared to a placebo in patients who had undergone a Kasai hepatoportoenterostomy. Biliary atresia, a rare liver disease in infants, remains a leading cause of pediatric liver transplants, often necessitating surgery or transplantation as no medical treatments exist.
The trial included 254 patients across 19 countries but showed no improvement in native liver survival. Despite the setback, the trial provided valuable data on this complex disease. Ipsen acknowledged the contributions of participants and emphasized the ongoing need for research in this area.
Bylvay, an ileal bile acid transport inhibitor, is currently approved for other liver conditions but has not shown efficacy in biliary atresia through this study. Further analysis of the trial's comprehensive data is anticipated to yield insights into disease biology and potential future treatments.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de IPSEN